ArticleDiscover oncology2025
Potential value of m6A-related lncRNAs in diagnosis and therapy of pancreatic cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pancreatic cancer is one of the digestive tract malignancies, and five-year overall survival rate of PAAD patients remains low. m6A can modify lncRNAs that could affect cancer cell proliferation and migration, it is of great significance to explore the mechanism of m6A-related lncRNA in the development of pancreatic cancer. In our study, 130 lncRNAs with a co-expression relationship with m6A genes were obtained by TCGA dataset analysis. A new prognostic model was constructed to predict overall survival in pancreatic cancer patients. Kaplan-Meier analysis, principalcomponent analysis (PCA), functional enrichment annotation, and nomogram were used to analyze the risk model. In addition, the relationship with the response to immunotherapy was explored. Finally, therapeutic agents targeting m6A-related lncRNA action targets were screened using the drug sensitivity database. In conclusion, our study highlighted the prognostic value of m6A-related lncRNAs in pancreatic cancer. We constructed a predictive model with high prognostic value and showed sensitivity in identifying patients with pancreatic cancer who may respond well to immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.